Announced
Completed
Synopsis
Sanofi, a French multinational pharmaceutical company, completed the acquisition of Tidal Therapeutics, a privately owned, pre-clinical stage biotech company, for $310m. "We anticipate that this next generation, off-the-shelf approach has the potential to bring CAR-T cell therapy to a much broader patient population. We believe that the underlying mRNA targeting platform will create disruptive therapeutic approaches across a variety of oncology and autoimmune conditions," Frank Nestle, Sanofi Global Head of Research and Chief Scientific Officer.
Principals
Show Details & Financials
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.